Tailored treatment strategies should also be adopted based on tumor characteristics and patient factors, and more biomarkers, such as MSI status, HER-2 positivity or ctDNA, may provide additional useful information for treating pT3N0M0 GC. The gene discussed is ERBB2; the disease is neoplasm.